Gastrointestinal HCO3− transport and epithelial protection in the gut: new techniques, transport pathways and regulatory pathways

Ursula Seidler(Medizinische Hochschule Hannover)

Current Opinion in Pharmacology

October 26, 2013

10.1016/j.coph.2013.10.001

Cited by 51

Related Papers

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

|New England Journal of Medicine|2016|1.8k

Probiotic Escherichia coli Nissle 1917 Inhibits Leaky Gut by Enhancing Mucosal Integrity

|PLoS ONE|2007|478

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

|The Lancet|2021|452

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

|The Lancet|2017|449

Intestinal Secretory Defects and Dwarfism in Mice Lacking cGMP-Dependent Protein Kinase II

|Science|1996|409